SCHEMBL6133076

SCHEMBL6133076

Cn1cc(CCNC=O)cn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.38
ALDH1A1 P00352 3/20 0.38
L3MBTL1 Q9Y468 3/20 0.38
HTT P42858 1/20 0.38
GAA P10253 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
HAT1 O14929 2/20 0.37
EP300 Q09472 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
HSD17B10 Q99714 1/20 0.37
OPRM1 P35372 1/20 0.35
OPRK1 P41145 1/20 0.35
JAK2 O60674 1/20 0.34
JAK1 P23458 1/20 0.34
JAK3 P52333 1/20 0.34
KCNH2 Q12809 1/20 0.34
TP53 P04637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16708779 0.82 SMN1; SMN2 (0.46) PDE10ASMN1; SMN2ALDH1A1L3MBTL1HTT
SCHEMBL7469718 0.80 ALDH1A1 (0.40) PDE10ASMN1; SMN2ALDH1A1L3MBTL1HTT
SCHEMBL3509780 0.78 PDE10A (0.45) PDE10ASMN1; SMN2ALDH1A1L3MBTL1HTT
SCHEMBL22267907 0.76 SIGMAR1 (0.50) PDE10ASMN1; SMN2ALDH1A1L3MBTL1HTT
SCHEMBL22267906 0.74 EP300 (0.43) PDE10ASMN1; SMN2ALDH1A1L3MBTL1HTT
SCHEMBL4509000 0.74
SCHEMBL30600853 0.73 NPC1 (0.46) PDE10ASMN1; SMN2ALDH1A1L3MBTL1HTT
SCHEMBL17273755 0.73 HCAR2 (0.49) SMN1; SMN2ALDH1A1GAANPC1RAB9A
SCHEMBL8342570 0.71
SCHEMBL7941493 0.71 PDE8B (0.38) PDE10ASMN1; SMN2ALDH1A1L3MBTL1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050004094-A1 Cephem compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-01-06 US disclosed
WO-2004101571-A1 CEPHEM COMPOUNDS FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2004-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004094-A1 Cephem compounds CEP170, C1S, CEPT1 PDE10A 635/4885SMN1; SMN2 1176/4885ALDH1A1 2105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.